Navigation Links
Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
Date:8/24/2009

lion doses of IMVAMUNE(R) and we look forward to exploring this exciting opportunity."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE(R), a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
9. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
10. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Israel, April 7 InSightec Ltd. announced,today that the ... for the company,s ExAblate(R) 2000 MR-guided Focused Ultrasound,(MRgFUS) system ... Under the new labeling, the agency allows,physicians to treat ... previous,restriction to only treat up to half the fibroid ...
... -- China Sky One,Medical, Inc. ("China Sky One ... ), a,leading fully integrated pharmaceutical company producing,over-the-counter drugs ... that an extension notification filed with the Securities ... 10-K on March 31, 2009, is,related to a ...
... Filtration and Separations Society (AFS) will be holding its 22nd ... Minnesota. , ... Minneapolis, MN (PRWEB) April 7, 2009 ... be holding its 22nd Annual Conference, May 4-7, 2009 at the ...
Cached Biology Technology:FDA Approves Label Change for Non-Invasive Fibroid Treatment 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 3China Sky One Medical, Inc. Provides Update on Filing Form 10-K 2China Sky One Medical, Inc. Provides Update on Filing Form 10-K 3University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 2University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 3
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... UCLA and a team of enterprising UCLA scientists envisioning a ... In 1996, a unique collaboration of leading UCLA scientists ... Inc. and the company now stands to reap $537 ... one of the largest Los Angeles-based private biotech firms poised ...
... gallons of hazardous waste resulting from the nations nuclear ... Washington state called Hanford. Beneath this desert landscape ... thousands of tons of chemicals are captured within the ... subsurface flow paths. These paths create uncertainties about ...
... making, Birds of Peru describes the birds of Peru ... in color, and concise descriptive text. The first two ... Douglas Stotz, PhD, are conservation ecologists and ornithologists in ... Museum will host a free public event launching the ...
Cached Biology News:Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3Where does stored nuclear waste go? 2Lavishly illustrated guide to Peru's birds describes 1,800 species 2
...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products: